Cell Therapy: A Novel Treatment Approach for Bronchopulmonary Dysplasia

Vosdoganes, Patricia; Lim, Rebecca; Moss, Timothy; Wallace, Euan M.

doi:10.1542/peds.2011-2576

Cited by 32 publications

(25 citation statements)

References 113 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preliminary animal and in vitro studies are currently exploring the possibility of use of other cell therapy options including embryonic stem cells, amniotic fluid stem cells, placental stem cells, and endogenous lung stem cells 97 . The research and field of cell therapy for prevention or treatment of BPD is growing 98 .…”

Section: Introductionmentioning

confidence: 99%

An update on pharmacologic approaches to bronchopulmonary dysplasia

Ghanta

Leeman

Christou

2013

Seminars in Perinatology

View full text Add to dashboard Cite

Bronchopulmonary dysplasia (BPD) is the most prevalent long-term morbidity in surviving extremely preterm infants and is linked to increased risk of reactive airways disease, pulmonary hypertension, post-neonatal mortality, and adverse neurodevelopmental outcomes. BPD affects approximately 20% of premature newborns, and up to 60% of premature infants born before 26 completed weeks of gestation. It is characterized by the need for assisted ventilation and/or supplemental oxygen at 36 weeks’ postmenstrual age. Approaches to prevention and treatment of BPD have evolved with improved understanding of its pathogenesis. This review will focus on recent advancements and detail current research in pharmacotherapy for BPD. The evidence for both current and potential future experimental therapies will be reviewed in detail. As our understanding of the complex and multifactorial pathophysiology of BPD changes, research into these current and future approaches must continue to evolve.

show abstract

Section: Introductionmentioning

confidence: 99%

An update on pharmacologic approaches to bronchopulmonary dysplasia

Ghanta

Leeman

Christou

2013

Seminars in Perinatology

View full text Add to dashboard Cite

show abstract

“…Cell therapies offer great promise for the prevention and treatment of tissue injury in newborns [55,56]. The placenta offers a rich source of therapeutic cell types, and the amnion, in particular, offers exciting possibilities for perinatal therapy.…”

Section: Postnatal Therapiesmentioning

confidence: 99%

Ventilation-Induced Brain Injury in Preterm Neonates: A Review of Potential Therapies

Barton

Tolcos²,

Miller

et al. 2016

Neonatology

Self Cite

View full text Add to dashboard Cite

Mechanical ventilation is a risk factor for cerebral inflammation and brain injury in preterm neonates. The risk increases proportionally with the intensity of treatment. Recent studies have shown that cerebral inflammation and injury can be initiated in the delivery room. At present, initiation of intermittent positive pressure ventilation (IPPV) in the delivery room is one of the least controlled interventions a preterm infant will likely face. Varying pressures and volumes administered shortly after birth are sufficient to trigger pathways of ventilation-induced lung and brain injury. The pathways involved in ventilation-induced brain injury include a complex inflammatory cascade and haemodynamic instability, both of which have an impact on the brain. However, regardless of the strategy employed to deliver IPPV, any ventilation has the potential to have an impact on the immature brain. This is particularly important given that preterm infants are already at a high risk for brain injury simply due to immaturity. This highlights the importance of improving the initial respiratory support in the delivery room. We review the mechanisms of ventilation-induced brain injury and discuss the need for, and the most likely, current therapeutic agents to protect the preterm brain. These include therapies already employed clinically, such as maternal glucocorticoid therapy and allopurinol, as well as other agents, such as erythropoietin, human amnion epithelial cells and melatonin, already showing promise in preclinical studies. Their mechanisms of action are discussed, highlighting their potential for use immediately after birth.

show abstract

“…BPD leads to distal airway epithelial cell simplification and vascular injury, and most current treatments are palliative (Ghanta, Leeman, & Christou, 2013). Bone marrow-derived MSCs and umbilical cord-derived MSCs have been shown to ameliorate lung injury in hyperoxia mouse models of BPD (Aslam et al, 2009; van Haaften et al, 2009; Vosdoganes, Lim, Moss, & Wallace, 2012). Low levels of MSC cell engraftment and an even greater preventative effect with delivery of cell-free MSC-conditioned media support the importance of a paracrine effect.…”

Section: Mscs: Potential Role Of Cell-based Therapy In Lung Diseasementioning

confidence: 99%

Lung Stem and Progenitor Cells in Tissue Homeostasis and Disease

Leeman

Fillmore

Kim

2014

Current Topics in Developmental Biology

View full text Add to dashboard Cite

The mammalian lung is a complex organ containing numerous putative stem/progenitor cell populations that contribute to region-specific tissue homeostasis and repair. In this review, we discuss recent advances in identifying and studying these cell populations in the context of lung homeostasis and disease. Genetically engineered mice now allow for lineage tracing of several lung stem and progenitor cell populations in vivo during different types of lung injury repair. Using specific sets of cell surface markers, these cells can also be isolated from murine and human lung and tested in 3D culture systems and in vivo transplant assays. The pathology of devastating lung diseases, including lung cancers, is likely in part due to dysregulation and dysfunction of lung stem cells. More precise characterization of stem cells with identification of new, unique markers; improvement in isolation and transplant techniques; and further development of functional assays will ultimately lead to new therapies for a host of human lung diseases. In particular, lung cancer biology may be greatly informed by findings in normal lung stem cell biology as evidence suggests that lung cancer is a disease that begins in, and may be driven by, neoplastic lung stem cells.

show abstract

Cell Therapy: A Novel Treatment Approach for Bronchopulmonary Dysplasia

Cited by 32 publications

References 113 publications

An update on pharmacologic approaches to bronchopulmonary dysplasia

An update on pharmacologic approaches to bronchopulmonary dysplasia

Ventilation-Induced Brain Injury in Preterm Neonates: A Review of Potential Therapies

Lung Stem and Progenitor Cells in Tissue Homeostasis and Disease

Contact Info

Product

Resources

About